Gentium S.p.A Earnings: What Investors Should Watch

Gentium S.p.A (NASDAQ:GENT) will report earnings before markets open on Thursday, March 28th. Gentium Spa is a biopharmaceutical company focused on the discovery, research, development and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments.

Here is your Cheat Sheet to Gentium S.p.A Earnings:

Earnings Expectations: Analysts expect earnings of $-0.03 per share on revenues of $8.57 million. Currently, the company’s P/E ratio stands at 368.57.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.09 to a profit $0.04. For the current year, the average estimate is a loss of $0.02, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Gentium S.p.A has been performing on an annual basis:

Fiscal Year 2007 2008 2009 2010 2011
Revenue ($) in millions 10.43 10.94 14.18 32.60 30.27
Diluted EPS ($) -1.85 -1.95 -0.41 0.38 0.23

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Sep. 30, 2011 Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012
Revenue ($) in millions 7.20 7.75 7.21 10.96 9.42
Diluted EPS ($) 0.00 0.01 -0.08 0.06 0.02

Past Performance:
Gentium S.p.A has beat analyst estimates 2 times in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]